These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 39210583)

  • 1. Real-world treatment costs of first-line treatment for metastatic colorectal cancer: a survey of the JCOG colorectal cancer study group.
    Takashima A; Ishiguro M; Sasaki K; Machida R; Nagashima F; Imaizumi J; Hamaguchi T; Yamamoto Y; Masuishi T; Asayama M; Ueno H; Shinozaki K; Kudo T; Machida N; Matsuoka H; Ishida H; Yamaguchi T; Nogami H; Yamada T; Takegawa N; Kito Y; Tonoike Y; Sawada R; Tsukamoto S; Kanemitsu Y;
    Jpn J Clin Oncol; 2024 Oct; 54(10):1107-1114. PubMed ID: 39210583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world cost analysis of chemotherapy for colorectal cancer in Japan: detailed costs of various regimens during the entire course of chemotherapy.
    Yajima S; Shimizu H; Sakamaki H; Ikeda S; Ikegami N; Murayama JI
    BMC Health Serv Res; 2016 Jan; 16():2. PubMed ID: 26728154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
    Shiroiwa T; Fukuda T; Tsutani K
    Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy.
    Johnston S; Wilson K; Varker H; Malangone-Monaco E; Juneau P; Riehle E; Satram-Hoang S; Sommer N; Ogale S
    Clin Colorectal Cancer; 2017 Dec; 16(4):386-396.e1. PubMed ID: 28619608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status of the cost burden of first-line systemic treatment for patients with advanced hepatocellular carcinoma in Japan, 2021-22.
    Imaoka H; Sasaki K; Machida R; Nagano H; Satoi S; Ikeda M; Kobayashi S; Yamashita T; Okusaka T; Ido A; Hatano E; Miwa H; Ueno M; Nakao K; Shimizu S; Kuramochi H; Sakamori R; Tsumura H; Okano N; Shioji K; Shirakawa H; Akutsu N; Tsuji K; Ishii H; Umemoto K; Asagi A; Ueno M;
    Jpn J Clin Oncol; 2024 Oct; 54(10):1071-1077. PubMed ID: 38843879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Economic Evaluation of mFOLFOX6-based First-line Regimens for Unresectable Advanced or Recurrent Colorectal Cancer Using Clinical Decision Analysis].
    Shida T; Endo Y; Shiraishi T; Yoshioka T; Suzuki K; Kobayashi Y; Ono Y; Ito T; Inoue T
    Yakugaku Zasshi; 2018; 138(1):83-90. PubMed ID: 29311468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial.
    Wang H; Huang L; Gao P; Zhu Z; Ye W; Ding H; Fang L
    BMJ Open; 2020 Feb; 10(2):e030738. PubMed ID: 32051297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
    Graham CN; Hechmati G; Fakih MG; Knox HN; Maglinte GA; Hjelmgren J; Barber B; Schwartzberg LS
    J Med Econ; 2015; 18(8):619-28. PubMed ID: 25822327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost of medical care for malignant brain tumors at hospitals in the Japan Clinical Oncology Group brain-tumor study group.
    Motomura K; Sasaki K; Sugii N; Yamaguchi S; Inoue H; Oshima A; Tanaka K; Otani Y; Shirahata M; Shibahara I; Nagane M; Tsuzuki S; Matsutani T; Tsukamoto Y; Kijima N; Asano K; Ohno M; Inoue A; Mineharu Y; Miyake K; Mitobe Y; Hanihara M; Kawanishi Y; Deguchi S; Saito M; Matsuda R; Ujifuku K; Arita H; Sato Y; Yamashita S; Yonezawa U; Yamaguchi J; Momii Y; Ogawa T; Kambe A; Ohba S; Fukai J; Saito N; Kinoshita M; Sumi K; Otani R; Uzuka T; Takebe N; Koizumi S; Saito R; Arakawa Y; Narita Y;
    Jpn J Clin Oncol; 2024 Oct; 54(10):1123-1131. PubMed ID: 39223700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Out-of-pocket payment and cost-effectiveness of XELOX and XELOX plus bevacizumab therapy: from the perspective of metastatic colorectal cancer patients in Japan.
    Shiroiwa T; Fukuda T; Tsutani K
    Int J Clin Oncol; 2010 Jun; 15(3):256-62. PubMed ID: 20198398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A real-world survey on expensive drugs used as first-line chemotherapy in patients with HER2-negative unresectable advanced/recurrent gastric cancer in the stomach cancer study group of the Japan clinical oncology group.
    Nishina T; Boku N; Kurokawa Y; Sasaki K; Machida R; Yoshikawa T
    Jpn J Clin Oncol; 2024 Oct; 54(10):1100-1106. PubMed ID: 39180720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of
    Stintzing S; van Oostrum I; Pescott CP; Ronga P; Heeg B; Heinemann V
    J Med Econ; 2020 May; 23(5):448-455. PubMed ID: 31903807
    [No Abstract]   [Full Text] [Related]  

  • 13. Status of incremental costs of first-line treatment recommended in Japanese clinical guidelines for metastatic breast cancer patients.
    Iwatani T; Sasaki K; Machida R; Shien T; Hara F; Fujisawa T; Takano Y; Kobayashi Y; Saimura M; Koizumi K; Terada M; Sasada S; Saito K; Sumiyoshi M; Iwata H
    Jpn J Clin Oncol; 2024 Oct; 54(10):1093-1099. PubMed ID: 39178176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High cost of chemotherapy for gynecologic malignancies.
    Takahashi N; Seki T; Sasaki K; Machida R; Ishikawa M; Yunokawa M; Matsuoka A; Kagabu M; Yamaguchi S; Hiranuma K; Ohnishi J; Sato T
    Jpn J Clin Oncol; 2024 Oct; 54(10):1078-1083. PubMed ID: 39023439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer.
    Shi Y; Wan X; Tan C; Li J; Peng L
    Adv Ther; 2020 Feb; 37(2):847-859. PubMed ID: 31902066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Treatment Sequences of Chemotherapies and Targeted Biologics for Elderly Metastatic Colorectal Cancer Patients.
    Parikh RC; Du XL; Robert MO; Lairson DR
    J Manag Care Spec Pharm; 2017 Jan; 23(1):64-73. PubMed ID: 28025930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
    Graham CN; Hechmati G; Hjelmgren J; de Liège F; Lanier J; Knox H; Barber B
    Eur J Cancer; 2014 Nov; 50(16):2791-801. PubMed ID: 25219451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer.
    Han J; Xiao D; Tan C; Zeng X; Hu H; Zeng S; Jiang Q; She L; Yao L; Li L; Tang L; Ma J; Huang J; Shen L
    Cancer Control; 2020; 27(1):1073274820902271. PubMed ID: 32107929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
    da Silva WC; de Araujo VE; Lima EMEA; Dos Santos JBR; Silva MRRD; Almeida PHRF; de Assis Acurcio F; Godman B; Kurdi A; Cherchiglia ML; Andrade EIG
    BioDrugs; 2018 Dec; 32(6):585-606. PubMed ID: 30499082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.